PI3K and AKT: Unfaithful Partners in Cancer
AbstractThe phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway regulates multiple cellular processes. An overactivation of the pathway is frequently present in human malignancies and plays a key role in cancer progression. Hence, its inhibition has become a promising approach in cancer therapy. However, the development of resistances, such as the abrogation of negative feedback mechanisms or the activation of other proliferative signaling pathways, has considerably limited the anticancer efficacy of PI3K/AKT inhibitors. In addition, emerging evidence points out that although AKT is acknowledged as the major downstream effector of PI3K, both PI3K and AKT can operate independently of each other in cancer, revealing another level of complexity in this pathway. Here, we highlight the complex relationship between PI3K and AKT in cancer and further discuss the consequences of this relationship for cancer therapy. View Full-Text
- Supplementary File 1:
Supplementary (PDF, 630 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Faes, S.; Dormond, O. PI3K and AKT: Unfaithful Partners in Cancer. Int. J. Mol. Sci. 2015, 16, 21138-21152.
Faes S, Dormond O. PI3K and AKT: Unfaithful Partners in Cancer. International Journal of Molecular Sciences. 2015; 16(9):21138-21152.Chicago/Turabian Style
Faes, Seraina; Dormond, Olivier. 2015. "PI3K and AKT: Unfaithful Partners in Cancer." Int. J. Mol. Sci. 16, no. 9: 21138-21152.